NeuroMetrix (NASDAQ:NURO) Earns Sell Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of NeuroMetrix (NASDAQ:NURO) in a research report issued to clients and investors on Friday. The brokerage set a “sell” rating on the medical device company’s stock.

NeuroMetrix Price Performance

NASDAQ NURO opened at $4.50 on Friday. The company has a market cap of $9.24 million, a P/E ratio of -0.98 and a beta of 2.15. NeuroMetrix has a 12 month low of $2.66 and a 12 month high of $4.73. The company has a 50-day moving average of $4.34 and a 200-day moving average of $4.14.

Hedge Funds Weigh In On NeuroMetrix

An institutional investor recently bought a new position in NeuroMetrix stock. Renaissance Technologies LLC acquired a new position in shares of NeuroMetrix, Inc. (NASDAQ:NURO) in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 11,560 shares of the medical device company’s stock, valued at approximately $46,000. Renaissance Technologies LLC owned about 0.57% of NeuroMetrix as of its most recent SEC filing. 19.40% of the stock is owned by institutional investors.

NeuroMetrix Company Profile

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.